Les meilleurs doctors à Istanbul pour votre Une greffe de moelle osseuse - TOP 25 des médecins

Le professeur MD Zafer Gulbas est spécialiste en oncologie médicale et hématologie, directeur de l'oncologie médicale au centre médical Anadolu et fondateur du centre de transplantation de moelle osseuse à Anadolu. Il est un hématologue-oncologue hautement qualifié, spécialisé dans la greffe de moelle osseuse, diplômé de la faculté de médecine de l'université Hacettepe, de la faculté de médecine de l'université d'Anadolu, du centre des maladies pulmonaires et de chirurgie thoracique d'Atatürk, du centre médical Hadassah, du centre de recherche sur le cancer Fred Hutchinson, du centre de recherche sur le cancer MDAnderson. et l'hôpital Princess Margaret de l'Université de Toronto.

Le Dr Şebnem İzmir Güner est un hématologue et oncologue turc qui a travaillé dans de nombreux hôpitaux prestigieux et est titulaire d'une maîtrise en administration de l'Université de Marmara. Elle est une spécialiste expérimentée en transplantation de moelle osseuse avec une formation avancée en aphérèse thérapeutique et est l'auteur ou le co-auteur de plusieurs articles médicaux. Le Dr Güner a également reçu de nombreux prix et est membre de plusieurs associations médicales.

Mustafa Solak, MD est un médecin diplômé de l'École de médecine de l'Université Hacettepe et a effectué des résidences à l'hôpital d'enseignement et de recherche Sisli Etfal d'Istanbul et une bourse à l'Institut du cancer de l'Université Hacettepe. Il se spécialise dans le cancer du sein, le cancer des testicules, le cancer de l'ovaire, le cancer du poumon, le cancer de la tête et du cou et les cancers gastro-intestinaux. Il a également travaillé au MD Anderson Cancer Center de l'Université du Texas, au Hitit University Corum Training Hospital et au Medical Park Hospital.

Areas of Interest

1. Bone marrow transplantation
2. Leukemia
3. Lymphoma
4. Multiple myeloma
5. Thalassemia
6. Bone marrow diseases
7. Plasmapheresis

Education
2005 Graduated from Hacettepe University, Faculty of Medicine
2010 Hacettepe University, Faculty of Medicine Internal Medicine Specialist
2014 Ankara University, Faculty of Medicine Hematology Specialist

Experience
October 2010 - December 2010 Internal Medicine Specialist at Ankara Oncology Hospital
December 2010 - April 2011 Hematology Sub-branch Assistant at Ankara Oncology Hospital
September 2014 - May 2016 Hematology Specialist at Kütahya Dumlupınar University Evliya Çelebi Training and Research Hospital
May 2016 - March 2018 Ufuk University, Faculty of Medicine, Hematology Department Faculty Member
March 2018 - October 2018 Hitit University, Faculty of Medicine, Hematology Department Faculty Member
November 2018 - January 2019 Medical Park Bahçelievler Hematology and Bone Marrow Transplantation Unit physician
February 2019 - June 2022 Present Bayındır Söğütözü Hospital Hematology and Stem Cell Transplantation Unit, Assistant Physician in Charge
June 2022 - July 2022 Afyonkarahisar Health Sciences University, Head of Hematology Department

Qualification Certificates
Internal Medicine Board Qualification Certificate, 2009
Hematology Board Qualification Certificate, 2014
English Proficiency 2017/7 e-YDS Score: 71.25
Internal Medicine Specialization Thesis Addition of 9-Week Trastuzumab to Adjuvant Treatment in Both Positive Breast Cancer Patients Retrospective Analysis

Education Abroad
Between October and December 2007 (3 months) Intensive Care Education at University of Florida, United States
Between December 2013 and January 2014 (2 months) Flow Cytometry Education at Salamanca University, Spain

Courses, Awards, and Certificates
1 Year of Work Certificate in Bone Marrow Transplantation, 2017
Blood Banking and Transfusion Medicine Certificate 2017
“Physician of the Year” Award in Kütahya, 2014
Laboratory GMP, GLP, ISO /IEC 17025: 2012 Certificates, 2014
Good Clinical Practices Certificate, 2013
Şeref Zileli Successful Assistant of the Year Award, 2009
RIA Certificate, 2005

Research and Publications

Patent
1. Half antibody with the fc portion removed (fab) for medical use. Inventor: Mehmet Özen. No:2016/0910. Patent under review.

Scientific Studies
A. Publications in International Journals under SCI Expanded


 Turkish book section

1. Ozen M, Konuk N. Immune thrombocytopenic purpura. Turkoz Sucak G, editor. Current Topics in Immunohematology. 1st Edition. Ankara: Turkey Clinics; 2021. p.8-12.

2. Özen M, Ural AU. Hematological diseases and mesenchymal stem cell applications. Türköz Sucak G, editor. Current Topics in Immunohematology. 1st Edition. Ankara: Turkey Clinics; 2021. p.91-4.

3. Ozen M. Hematopoiesis and Hematopoietic Growth Factors. MediHealth & Hippocrates INTERNAL DISEASES with Current Guidelines 2022. p1607-10

Education

• Ege Faculty of Medicine 1978
• Specialization in Pediatrics 1982
• Subspecialty Pediatric Oncology 2002 (EU Faculty of Medicine)
• Pediatric Hematology and Oncology 2012 (EU Faculty of Medicine)
• Deputy Chief of Clinic 1988 Tepecik EAH
• Clinical Chief 1993 Tepecik EAH
• Associate Professorship 1995
• Professorship  2002
• Ege U. Faculty of Medicine, faculty member 1998 – 2022
• EU Faculty of Medicine Department of Pediatrics 2009-2018
• Member of Tepecik Education Planning and Coordination Board (1993-1998)
• SSI Tepecik Hospital Ethics Committee Chairman (1996-1998)
• Turkish Society of Pediatric Hematology "Bone Marrow Transplantation Working Group Co-Chair" (2002-2006)
• Turkish Society of Pediatric Hematology "Bone Marrow Transplantation Working Group" (2006-2008)
• Turkish Society of Pediatric Hematology - Responsible for Bone Marrow Transplantation "Online" Data Registry System 2007-ongoing.
• Ege University Regenerative Medicine and Stem Cell Commission Chairman, 2011-2021

Institutional Memberships

• Turkish Medical Association İzmir and Kocaeli Branch
• Turkish National Pediatric Association - İzmir
• European Group for Bone Marrow Transplantation (EBMT); Ege University Pediatric Bone Marrow Transplantation Unit was accredited by the European Group for Bone Marrow Transplantation (EBMT) in June 2007.
• Turkish Society of Pediatric Hematology - Board Member for two terms (2005-2009)
• Turkish Society of Hematology - Board Member for two terms (2001/2005)
• Turkish Pediatric Oncology Association
• Bone Marrow Transplantation Foundation (KITVAK) Member of the Board of Trustees

Units he is the founder of                        

1- SSI Tepecik Hospital Pediatric Oncology Clinic (1990) 
2- SSI Tepecik Hospital Pediatric Bone Marrow Transplantation Unit (1992) 
3- EU Faculty of Medicine Pediatric Bone Marrow Transplantation Unit (1998) 
4- FOUNDER of JOURNAL OF PEDIATRIC RESEARCH, 2014; SCI application was made in 2022.  

Transplantation units that he contributed to the establishment of                        

1. İzmir BUÇH EAH Pediatric Bone Marrow Transplantation Unit (2019) 
2. Ümraniye EAH Pediatric Bone Marrow Transplantation Unit (2020) 
3. Kanuni Sultan Süleyman EAH Pediatric Bone Marrow Transplantation Unit (2020) (Transferred to Çam Sakura EAH)

Awards

• Thrombotic parameters in bone marrow stem cell transplant patients, Pediatric Hematology Congress, Trabzon 2003
• CD133 Antigen in Stem Cell: Pediatric Hematology Congress 2005. Research award
• The role of Toll like receptors in febrile neutropenic patients, Best poster award. Turkish Hematology Congress 2008, Çeşme-İzmir
• National pediatric stem cell transplantation activity- Oral presentation second prize, Turkish Hematology Society Stem Cell Transplantation Congress, 2022, Antalya

Publications

Kansoy S. "Bone Marrow and Stem Cell Transplantation Child Health and Diseases, 1st edition, EU Faculty of Medicine Printing House, 1999, İzmir

Kansoy S. Bone marrow transplantation in Thalassemia Major III. Aegean Thalassemia Days Book, 2000, Izmir

Kansoy S. Pediatric KIT Center Standards in Turkey. Childhood Acute Leukemias, Antalya 2000: 73-5

Kansoy S. Late Side Effects in Children. Special issue of Bone Marrow Transplantation Journal of Turkish Clinics. 2003

Kansoy S. Stem Cell Applications in Bone Marrow and Stem Cell Transplantation. Pediatric Oncology Nursing Course Book, İzmir, 2005

Kansoy S. Cord Blood as a Stem Cell Source. Stem Cell Special Issue. Turkey Clinics, 2008

Kansoy S. Stem Cell Transplantation in Lymphomas. General Pediatrics Book, Ed. Prof.Dr.Enver Hasanoglu, 2009

Kansoy S, Aksoylar S. Bone Marrow Transplantation in Children. Pediatrics, 2014 and 2017

Kansoy S. Rhabdomyosarcoma. Pediatrics, 2014 and 2017

Kansoy S. Approach to the child with cancer according to clinical findings. Pediatrics, 2014 and 2017 

11. Çetingül N, S.Kansoy, M.Kantar. Oncological Diseases. Pediatrics (Ed. A. Cura), 641-672, Ege University Print house, İzmir, 1999.  (1.05 points)

Kansoy S, M.Kantar. Head, Face and Eye Examination. Pediatric Prosthetic Physical Examination and Symptom Information (Ed. A.Cura)

Kantar M. Metabolic Emergency Problems in Oncology. Oncologic Emergencies and Supportive Care in Childhood (Ed. N. Çetingül, S. Kansoy), 15-24, Meta Basım, İzmir, 2003. 

Cord Blood Transplants in Turkey. HEMATOLOGIST, 2016

Kansoy S. Central Nervous System Tumors in Children Pediatrics, 2014 and 2017

Acute myeloblastic leukemia in children and its treatment. Pediatric Oncology Textbook, Poplack's Turkish, 2020

National pediatric stem cell transplant activity, 2020

Childhood stem cell transplantation indications, Turkey Clinics - International book 2020

In addition to the studies and papers in international journals published in large numbers, he is involved in international multicenter studies in some journals with high impact value.

Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.

He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as bone marrow transplantation.

MEDICAL INTERESTS 

Clotting Disorders (Thrombophilia)

Bleeding Disorders

Myeloproliferative Diseases

Anemias (Anemia)

Acute and Chronic Leukemias

lymphomas

Bone marrow transplantation

Professeur d'oncologie et d'hématologie

Assoc. Le professeur Ali Eser a reçu sa formation médicale à la faculté de médecine de l'université d'Uludağ ; Il a complété sa résidence en médecine interne à l'hôpital de formation et de recherche d'Istanbul et sa résidence en hématologie à l'Université de Marmara.

Par la suite, il a effectué son service obligatoire à la clinique d'hématologie de l'université de Marmara, d'abord à l'université de Çanakkale, puis à l'université Bezmialem Vakıf. Il a servi comme conférencier. Après avoir travaillé pendant 2 ans comme spécialiste en hématologie et médecin assistant responsable de l'unité de greffe de moelle osseuse adulte à l'hôpital intercontinental Hisar, il a travaillé comme maître de conférences à l'université Bezmialem Vakıf et dans l'unité de greffe de moelle osseuse adulte de l'université Yeniyüzyıl d'Istanbul, et enfin pendant 1 an. Il a travaillé pendant un certain temps comme médecin responsable de l'unité de transplantation de moelle osseuse adulte à l'hôpital Liv de Gaziantep. Il a reçu le titre de professeur associé en mars 2022.

Müge Gökçe est hématologue pédiatrique et cancérologue en Turquie, spécialisée dans les greffes de moelle osseuse. Elle a occupé des postes dans divers hôpitaux depuis 2001 et est diplômée en médecine générale, en pédiatrie et en hématologie et oncologie pédiatriques. Elle est membre de l'Association turque d'hématologie, de la Société turque d'hématologie pédiatrique et de la Société européenne de transplantation de sang et de moelle.

Education:

2015

Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

2010

Dokuz Eylül University, Medical Faculty, Internal Medicine 

2005

Hacettepe University, Medical Faculty,

Experience:

2024 – 

Istanbul Florence Nightingale Hospital

2017 – 2024

Bağcılar Medipol University Hospital

2017 – 2017

Fırat University

2015 - 2017

Fırat University

2014 - 2015

Mayo Clinic

Publications:

18 Articles Published in International Peer-Reviewed Journals

26 Abstracts and Books Presented at International Scientific Conferences

7 Articles Published in National Peer-Reviewed Journals

51 Abstracts Presented at National Scientific Conferences

Education and Expertise

Ankara University Faculty of Medicine - Medical Education

Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization

Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty

Duke University Bone Marrow Transplantation Center - Stem Cell Transplantation Training

Fred Hutchinson Cancer Research Center Seattle - Stem Cell Transplant Training

Experience

Duke University-Durham North Carolina Bone marrow transplantation program 2001, cord blood transplant

Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant

Founder and manager of Gazi University Faculty of Medicine Adult Stem Cell Transplant Unit 2003-2014

Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014

Gazi University Faculty of Health Sciences Dean (founder) 2008-2012

Professional Memberships

Turkish Hematology Association





Bilimsel Yayınları

1.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
    Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2.    Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3.    Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4.    Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201. 
5.    Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
7.    Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80. 
8.    van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9.    Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90. 
10.    Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7. 
11.    Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12.    Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40. 
13.    Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14.    Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015  Apr 28.
15.     Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20. 
16.    Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17.    Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18.    Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19.    Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20.    Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21.    Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22.    Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23.    Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62. 
24.    Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25.    Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318   Pages 323 – 324
26.    Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27.    Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28.    Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29.    Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30.    Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31.    Keser I, Suyani E, Aki SZ,  Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32.    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.  Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33.    Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34.    Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35.    Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36.    Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37.    Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
39.    Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40.    Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41.    Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43.    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44.    Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45.    Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46.    Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47.    Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48.    Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49.    Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells.J Endocrinol. 2012 Feb;212(2):169-78.
50.    Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51.    Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52.    Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53.    Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54.    Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55.    Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56.    Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57.    Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58.    Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59.    Ljungman P,  de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60.    Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61.    Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62.    Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63.    Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64.    Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65.    Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66.    Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67.    Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68.    Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
69.    Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.

Adult Hematology

Fields of Study and Interests

• Stem cell transplantation (bone marrow transplantation:

autologous/allogeneic)

• Acute leukemias (AML-ALL)

• Chronic leukemias

• Lymphomas (Hodgkin and non-Hodgkin lymphomas)

• Multiple myeloma

• Bone marrow deficiencies (Myelodysplastic syndrome - aplastic anemia etc.)

• Chronic myeloproliferative diseases (polycythemia vera - essential thrombocytosis - primary

myelofibrosis)

• Anemias / Polycythemias (anemia - excess blood)

• Outpatient and inpatient chemotherapies - immunotherapies - targeted therapies

Education

• Faculty of Medicine – Cerrahpaşa Faculty of Medicine 1999-2005

• Internal Medicine Specialist Training – İstanbul Haseki Training and Research Hospital

20062010

• Hematology Subspecialist Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research

Hospital – Hematology and Stem Cell Transplantation Clinic 2013-2017

• Associate Professor İstanbul Ümraniye Training and Research Hospital 2019

Career

• Assistant Doctor Istanbul Haseki Training and Research Hospital-Internal Medicine Clinic

20062010

• Internal Medicine Specialist Istanbul Esenyurt State Hospital 2010-2012

• Internal Medicine Specialist-Military Service Samsun Military Hospital 2012-2013

• Minor Specialization Training Dr. Abdurrahman Yurtaslan Ankara Oncology Training and

Research Hospital – Hematology and Stem Cell Transplantation Clinic 2013-2017

• Hematology Subspecialist Ankara Gülhane Training and Research Hospital, Hematology and

Stem Cell Transplantation Clinic 2017-2018

• Hematology Subspecialist Istanbul Ümraniye Training and Research Hospital/Hematology

2018-2019

• Associate Professor Istanbul Ümraniye Training and Research Hospital/Hematology 2019-2021

• Associate Professor Maltepe University Faculty of Medicine / Hematology 2021-2024

• Associate Professor Istanbul VM Medical Park Pendik Hospital / Hematology and Stem Cell

Transplantation Clinic 2022-2024